2seventy bio Past Earnings Performance
Past criteria checks 0/6
2seventy bio has been growing earnings at an average annual rate of 2.2%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 8.2% per year.
Key information
2.2%
Earnings growth rate
25.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 8.2% |
Return on equity | -85.2% |
Net Margin | -216.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts
Mar 072seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%
Feb 06Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation
Jan 172seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth
Dec 13Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts
May 05Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%
Mar 212seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates
Mar 19We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate
Oct 042seventy Bio: This Spinoff In The CAR-T Space Is Attractive
Sep 082seventy bio Prospects
Aug 23Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook
Aug 122seventy bio GAAP EPS of -$2.02 misses by $0.09, revenue of $13.48M misses by $3.04M
Aug 10Revenue & Expenses BreakdownBeta
How 2seventy bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 100 | -218 | 69 | 218 |
30 Sep 23 | 146 | -184 | 72 | 0 |
30 Jun 23 | 147 | -180 | 79 | 0 |
31 Mar 23 | 125 | -215 | 76 | 0 |
31 Dec 22 | 91 | -254 | 79 | 230 |
30 Sep 22 | 51 | -292 | 85 | 0 |
30 Jun 22 | 57 | -284 | 89 | 0 |
31 Mar 22 | 51 | -291 | 93 | 0 |
31 Dec 21 | 55 | -292 | 94 | 223 |
30 Sep 21 | 48 | -308 | 91 | 0 |
30 Jun 21 | 48 | -320 | 90 | 0 |
31 Mar 21 | 150 | -222 | 92 | 0 |
31 Dec 20 | 248 | -120 | 91 | 0 |
31 Dec 19 | 44 | -321 | 82 | 0 |
31 Dec 18 | 55 | -200 | 54 | 0 |
Quality Earnings: TSVT is currently unprofitable.
Growing Profit Margin: TSVT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TSVT is unprofitable, but has reduced losses over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare TSVT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TSVT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: TSVT has a negative Return on Equity (-85.22%), as it is currently unprofitable.